Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237100 · ClinicalTrials.gov registry record · Phase 2
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
A Phase 2 study of Metastatic Melanoma and Advanced Unresectable Melanoma, sponsored by Kevin Kim, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07237100 is a Phase 2 study of Metastatic Melanoma and Advanced Unresectable Melanoma that is actively recruiting participants, run by Kevin Kim, MD. The registered enrollment target is 10 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07237100, a Phase 2 study of Metastatic Melanoma and Advanced Unresectable Melanoma, is actively recruiting participants, sponsored by Kevin Kim, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy. The main questions this study aims to answer are: * To evaluate the feasibility of conducting a prospective single-center clinical trial of mirdametinib in patients with advanced NF1-mutant melanoma whose disease progresses during or after PD-1 antibody-based checkpoint inhibitor therapy. * To evaluate preliminary clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy * To evaluate the safety profile of mirdametinib in patients with advanced NF1-mutant melanoma
Conditions Studied
Interventions
- DRUG Mirdametinib
Study Locations (1)
California
- California Pacific Medical Center - Sutter Health - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2030-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07237100
The ClinicalTrials.gov registry entry for NCT07237100 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (88% lower). The listed sponsor is Kevin Kim, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Mirdametinib is the first listed.
NCT07237100 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07237100 about?
NCT07237100 is a clinical study titled "Mirdametinib in Patients With Advanced NF1-mutant Melanoma". The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy. The main questions this study aims to answer are: * To evaluate the feasibility of conducting a prosp...
What is the current status of trial NCT07237100?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-10-13. Estimated completion is 2030-10-13.
What conditions does trial NCT07237100 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Advanced Unresectable Melanoma.
What interventions are being tested in trial NCT07237100?
The interventions under investigation include: Mirdametinib (DRUG).
Who is sponsoring clinical trial NCT07237100?
This trial is sponsored by Kevin Kim, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07237100 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
-
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.